MedTrace Logo

A Study Of BOTOX For The Treatment Of Glabellar Lines

NCT00408785 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2017-05-31

No results posted yet for this study

Summary

This is a Multicenter, double-blind, randomized, placebo-controlled, parallel-group comparative study to confirm the efficacy and safety of BOTOX 20 units single injection for the Chinese patients with glabellar lines. The subjects will receive a single intramuscular treatment consisting of 5 injections of either BOTOX? 20U or placebo.

Conditions

  • Glabellar Lines

Interventions

DRUG

Botulinum Toxin Type A

botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg

DRUG

sodium chloride

sodium chloride 0.9 mg

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-01
Primary Completion
2007-05-09
Completion
2007-05-09

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00408785 on ClinicalTrials.gov